BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19173791)

  • 21. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis.
    Celik T; Turkoglu EB
    Curr Eye Res; 2014 Jan; 39(1):42-6. PubMed ID: 24074291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug.
    Ohmori K; Hayashi K; Kaise T; Ohshima E; Kobayashi S; Yamazaki T; Mukouyama A
    Jpn J Pharmacol; 2002 Apr; 88(4):379-97. PubMed ID: 12046981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.
    Shimura M; Yasuda K; Miyazawa A; Otani T; Nakazawa T
    Am J Ophthalmol; 2011 Apr; 151(4):697-702.e2. PubMed ID: 21257151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative activity of antihistamines on area under dose-response curve from histamine-induced wheal and flare responses in human skin].
    Wang RQ; Zhang HY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Dec; 26(6):634-8. PubMed ID: 15663222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation.
    Pipkorn P; Costantini C; Reynolds C; Wall M; Drake M; Sanico A; Proud D; Togias A
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):82-9. PubMed ID: 18681089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis.
    Meltzer EO; Hampel FC; Ratner PH; Bernstein DI; Larsen LV; Berger WE; Finn AF; Marple BF; Roland PS; Wall GM; Brubaker MJ; Dimas C; Potts SL; Silver LH; Barnes JR
    Ann Allergy Asthma Immunol; 2005 Dec; 95(6):600-6. PubMed ID: 16400902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of olopatadine hydrochloride, an anti-histamine drug, on rhinitis induced by intranasal instillation of toluene-2,4-diisocyanate in rats.
    Tamura T; Komai M
    Int Immunopharmacol; 2008 Jun; 8(6):916-21. PubMed ID: 18442798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety.
    Sil A; Tripathi SK; Chaudhuri A; Das NK; Hazra A; Bagchi C; Islam CN
    J Dermatolog Treat; 2013 Dec; 24(6):466-72. PubMed ID: 23163959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: suppressive effects on skin response to histamine iontophoresis.
    Morita E; Matsuo H; Zhang Y
    J Dermatol; 2005 Jan; 32(1):58-61. PubMed ID: 15841664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the sedating effects of levocetirizine and cetirizine: a randomized, double-blind, placebo-controlled trial.
    Tzanetos DB; Fahrenholz JM; Scott T; Buchholz K
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):517-22. PubMed ID: 22123381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
    Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
    J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
    Villareal AL; Farley W; Pflugfelder SC
    Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cetirizine inhibits bradykinin-induced cutaneous wheal and flare in atopic and healthy subjects.
    Fadel R; Ramboer I; Chatterjee N; Rihoux JP; Derde MP
    Allergy; 2000 Sep; 55(9):888-91. PubMed ID: 11003455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of topical vapocoolant spray on skin test wheal, flare, and pain responses.
    Waibel KH; Katial RK
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):149-53. PubMed ID: 16136764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis.
    Berger WE; Ratner PH; Casale TB; Meltzer EO; Wall GM
    Allergy Asthma Proc; 2009; 30(6):612-23. PubMed ID: 20031007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: a prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life.
    Okubo Y; Shigoka Y; Yamazaki M; Tsuboi R
    J Dermatolog Treat; 2013 Apr; 24(2):153-60. PubMed ID: 21810005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.